GlassScriptPhysician profile
Jason Min So
NPI 1801282249
$2,390.54
in general payments reported to CMS, 2019-2025
11 companies · $1,250 in 2025
The $1,250 reported for 2025 was more than what 78% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $137 · 2022: $556 · 2023: $230 · 2024: $218 · 2025: $1,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,697.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $414.45 | 2024-2025 | Izervay |
| Alimera Sciences, INC. | $405.07 | 2022-2024 | Yutiq, Iluvien |
| Harrow Eye, LLC | $315.24 | 2024-2025 | Iheezo, Triesence |
| Apellis Pharmaceuticals, INC. | $254.92 | 2023-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $249.96 | 2022-2025 | Eylea Hd |
| Genentech USA, INC. | $215.17 | 2024-2025 | Susvimo, Vabysmo |
| Bausch & Lomb Americas INC. | $193.24 | 2022-2023 | Xipere |
| Ani Pharmaceuticals, INC. | $179.24 | 2025 | Purified Cortrophin Gel, Iluvien |
| Eyevance Pharmaceuticals LLC | $116.96 | 2021 | |
| Abbvie INC. | $26.74 | 2024 | |
| Alcon Vision LLC | $19.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason So listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.